Investigational drug · Phase 2
EP0031
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EP0031"
First trial start
2022
Sep 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EP0031", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "EP0031" as an intervention, largest first.
Ellipses PharmaIndustry
NCT05443126 · 265 participants (planned) · Start Sep 30, 2022 · Primary completion Mar 2027
Drug: EP0031; Platinum chemotherapy and 1 more · For: NSCLC
Sites: Los Angeles, California; Stanford, California; Washington D.C., District of Columbia · 52 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- How to manage medullary thyroid carcinoma: current treatment strategies.
Saltiki K, Karapanou O, Michalaki M, et al. · Drugs Context 2026
Also in development for NSCLC
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.